NEW YORK (GenomeWeb News) – Danaher today reported sales in its Life Sciences & Diagnostics segment more than doubled in the second quarter from a year ago, while total revenues grew 25 percent.

For the three months ended June 29, the Life Sciences & Diagnostics business posted revenues of $1.58 billion, up 125 percent from $704.8 million a year ago as acquisitions added 123 percentage points to the growth while the segment's core business grew 5 percent year over year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.